Geode Capital Management LLC bought a new stake in Xenon Pharmaceuticals Inc (NASDAQ:XENE) during the 4th quarter, HoldingsChannel.com reports. The institutional investor bought 14,084 shares of the biopharmaceutical company’s stock, valued at approximately $88,000.
Other large investors have also recently modified their holdings of the company. Northern Trust Corp grew its holdings in Xenon Pharmaceuticals by 18.9% in the fourth quarter. Northern Trust Corp now owns 12,246 shares of the biopharmaceutical company’s stock worth $77,000 after purchasing an additional 1,948 shares during the period. Scotia Capital Inc. grew its holdings in Xenon Pharmaceuticals by 16.8% in the fourth quarter. Scotia Capital Inc. now owns 66,704 shares of the biopharmaceutical company’s stock worth $421,000 after purchasing an additional 9,618 shares during the period. Altshuler Shaham Ltd purchased a new stake in Xenon Pharmaceuticals in the fourth quarter worth about $618,000. BlackRock Inc. purchased a new stake in Xenon Pharmaceuticals in the fourth quarter worth about $1,790,000. Finally, Alps Advisors Inc. purchased a new stake in Xenon Pharmaceuticals in the fourth quarter worth about $365,000. 67.32% of the stock is currently owned by hedge funds and other institutional investors.
XENE has been the topic of a number of recent research reports. BidaskClub upgraded shares of Xenon Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, May 7th. Stifel Nicolaus restated a “buy” rating and issued a $18.00 price objective (down previously from $21.00) on shares of Xenon Pharmaceuticals in a report on Friday, March 29th. Finally, Zacks Investment Research cut shares of Xenon Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, February 23rd. One research analyst has rated the stock with a hold rating, two have issued a buy rating and two have given a strong buy rating to the company’s stock. Xenon Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $15.00.
Xenon Pharmaceuticals (NASDAQ:XENE) last announced its quarterly earnings data on Tuesday, May 7th. The biopharmaceutical company reported ($0.42) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.36) by ($0.06). As a group, equities analysts predict that Xenon Pharmaceuticals Inc will post -1.88 earnings per share for the current year.
COPYRIGHT VIOLATION NOTICE: “14,084 Shares in Xenon Pharmaceuticals Inc (XENE) Acquired by Geode Capital Management LLC” was originally posted by Baseball Daily News and is the property of of Baseball Daily News. If you are reading this article on another website, it was stolen and republished in violation of U.S. and international copyright & trademark law. The legal version of this article can be viewed at https://www.baseballdailydigest.com/news/2019/05/18/14084-shares-in-xenon-pharmaceuticals-inc-xene-acquired-by-geode-capital-management-llc.html.
About Xenon Pharmaceuticals
Xenon Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline include XEN496, A Kv7 potassium channel modulator that is phase II clinical trials for the treatment of KCNQ2 epilepsy; XEN1101, A Kv7 potassium channel modulator, which is in phase II clinical trail for the treatment of epilepsy.
Further Reading: What is a Swap?
Want to see what other hedge funds are holding XENE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Xenon Pharmaceuticals Inc (NASDAQ:XENE).
Receive News & Ratings for Xenon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.